Dicerna Pharmaceuticals, Inc. (DRNA) News

Dicerna Pharmaceuticals, Inc. (DRNA): $38.01

0.97 (+2.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

Filter DRNA News Items

DRNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DRNA News Highlights

  • 500 - Internal server error
  • Over the past 20 days, the trend for DRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest DRNA News From Around the Web

Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.

Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3

LEXINGTON, Mass., Jun 16, 2021--Dicerna announced it has completed dosing in the Company’s PHYOX™4 clinical trial, evaluating nedosiran for the treatment of patients with PH3.

Yahoo | June 16, 2021

2 Biotech Stocks ARK Invest Bought in June

Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over the past 12 months. On Jun. 3, 2021, the ARK Genomic Revolution ETF bought shares of these two clinical-stage biotechs.

Yahoo | June 7, 2021

Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference

Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference.

Yahoo | June 3, 2021

We Take A Look At Why Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) CEO Has Earned Their Pay Packet

We have been pretty impressed with the performance at Dicerna Pharmaceuticals, Inc. ( NASDAQ:DRNA ) recently and CEO...

Yahoo | May 28, 2021

Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469

Dicerna announced the U.S. FDA's acceptance of the Investigational New Drug (IND) application filed by Lilly for LY3819469.

Yahoo | May 27, 2021

Goldman Sachs Says These 3 Stocks Could Surge Over 70% From Current Levels

Are we at the start of a boom or a bust? That’s the question on investors’ minds these days, as the world gets back on its feet following the COVID crisis. The recent April jobs report, with its mix of good and bad news, puts the question into sharp relief. First, the good news. April saw 266,000 new jobs created. On the negative side, economists had predicted as many as 1 million. The expectation has been that this economic recovery will be heavily front-loaded regarding job recreation – the theory is, the jobs are there; they are just waiting for workers to go back to them. That’s not quite happening.

Michael Marcus on TipRanks | May 11, 2021

Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -39.29% and -20.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 6, 2021

Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update

Dicerna today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Yahoo | May 6, 2021

Dicerna Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.

Yahoo | May 6, 2021

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront

Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. The FDA and European Medicines Agency have approved Oxlumo (EMA) for the treatment of primary hyperoxaluria (PH) type 1 and is marketed by Alnylam Pharmaceuticals Inc (NASDAQ: ALNY). Dicerna became entitled to royalties on worldwide net product sales of Oxlumo as part of a 2020 non-exclusive intellectual property cross-license agreement between Dicerna and Alnylam related to the companies' PH programs. Dicerna is entitled to royalties in the mid to high single digits based on OXLUMO global net sales. This transaction, together with Dicerna's cash, ...

Yahoo | April 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7374 seconds.